| Issue Date | Title | Involved Person(s) |
| Oct-2019 | Real-world drug regimes for multiple myeloma in a Swiss population (2012 to 2017) : cost-outcome description | Eichler, Klaus; Rapold, Ronald; Wieser, Simon; Reich, Oliver; Blozik, Eva |
| 2018 | Die Schweiz zahlt hohen Preis für nicht-übertragbare Krankheiten : gesundheitsökonomische Studie identifiziert die teuersten Krankheiten der Schweiz | Huber, Carola; Wieser, Simon |
| 2018 | How much does the treatment of each major disease cost? A decomposition of Swiss National Health Accounts | Wieser, Simon; Riguzzi, Marco; Pletscher, Mark; Huber, Carola A.; Telser, Harry, et al |
| 2016 | Cost-effectiveness of price subsidies on fortified packaged infant cereals in reducing iron deficiency anemia in 6-23-month-old children in urban India | Plessow, Rafael; Arora, Narendra Kumar; Brunner, Beatrice; Wieser, Simon |
| 2015 | Social costs of iron deficiency anemia in 6–59-month-old children in India | Plessow, Rafael; Arora, Narendra Kumar; Brunner, Beatrice; Tzogiou, Christina; Eichler, Klaus, et al |
| 2013 | Inpatient hospital costs of febrile neutropenia as a consequence of chemotherapy for breast cancer and non-Hodgkin lymphoma in Switzerland | Mattli, Renato; Eichler, Klaus; Pletscher, Mark; Wieser, Simon |
| 2013 | Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland | Pletscher, Mark; Plessow, Rafael; Eichler, Klaus; Wieser, Simon |
| 2012 | Health economic modelling of the cost-effectiveness of microalbuminuria screening in Switzerland | Kessler, Reto; Keusch, Gérard; Szucs, Thomas; Wittenborn, John; Hoerger, Thomas, et al |
